To explore the role of PKC-α and Gal-3 in the transition of AKI to CKD, we first treated HEK293 cells with PKC-α activator PDB and its inhibitor chelerythrine, at 30 min after treatment with cisplatin or saline. This evidence concerns the gene PRKCA and acute kidney injury.